{'fraction_non_alphanumeric': 0.03547671840354767, 'fraction_numerical': 0.010347376201034738, 'mean_word_length': 5.478468899521531, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunotherapy of cervical intraepithelial neoplasia associated with human papillomavirus in the COVID-19 pandemic. Clinicians’ view

In the context of the COVID-19 pandemic, the connection between SARS-CoV-2 and other immune-dependent human conditions, including cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV), are being discussed. A review of the literature and the results of observation of patients who are currently receiving therapy with inosine pranobex (IP) according to the standard regimen (as the second stage after organ-preserving cervical surgery) indicate the absence of any abnormalities during the postoperative period. Moreover, publications on the interaction of IP and COVID-19 provide a chance for a favorable outcome regarding not only the treatment of CIN, but also minimizing the inflammatory syndrome in case of SARS-CoV-2 infection. Conclusion. The use of IP as medication-assisted (postoperative) treatment of patients with CIN-HPV in the COVID-19 pandemic conditions is, firstly, as effective with respect to cervical pathology as it is outside the pandemic; secondly, in case of SARS-CoV-2 infection, it can potentially reduce the severity of the course and consequences of respiratory viral infection. Key words: COVID-19, SARS-CoV-2, cervical intraepithelial neoplasia, inosine pranobex